

Hyperhaemolysis in sickle cell disease — an unusual and potentially life-threatening complication

Ian C Stokes, Peter A Downie, Erica M Wood, Donald K Bowden, Paul T Monagle and Chris D Barnes

As sickle cell disease is increasing in Australia, paediatricians and other health care providers need to be aware of the broad range of complications that can occur in this condition. Although the complications of splenic sequestration and chest crises are well recognised, the infrequent but equally dramatic complication of hyperhaemolysis is less well appreciated. Here, we report a case of hyperhaemolysis in a Victorian paediatric patient. (MJA 2010; 192: 281-282)

Clinical record

A 12-year-old boy with sickle cell disease (homozygous haemoglobin S) presented in July 2006 with abdominal pain and fever — symptoms of a vaso-occlusive crisis. His usual baseline haemoglobin level ranged from 65 g/L to 75 g/L. He was thriving, but had a history of numerous vaso-occlusive crises. His past management included repeated transfusions with Rhesus and Kell phenotypically matched, leukocyte-depleted (LD) red cells. During this admission, he was managed with intravenous (IV) fluids, IV analgesia, antibiotics and a transfusion of 1 unit of phenotypically matched, crossmatch compatible, LD red cells. His pain gradually resolved and he was discharged home.

Twenty-four hours after discharge (7 days after the transfusion), he re-presented with marked lethargy, jaundice, tachycardia, and no increase in splenic size. His haemoglobin level was 45 g/L and reticulocyte count was increased, at $444 \times 10^9/L$ (reference range, $20\text{--}200 \times 10^9/L$). He received a transfusion of a further 2 units of red cells (about 500 mL). However, he remained pale after the transfusion and his haemoglobin level had further decreased to 39 g/L. He also developed profuse haemoglobinuria.

Based on his estimated blood volume of 2350 mL, the total transfusion of 750 mL during the two admissions would equate to an increase in haemoglobin of 55 g/L, so the observed drop in haemoglobin level was consistent with haemolysis of both recipient and donor red cells. No red cell alloantibodies or autoantibodies were detected. A presumptive diagnosis of sickle cell hyperhaemolysis syndrome was made. Further transfusions were avoided, and the patient was treated with IV immunoglobulin (IVIg) (1 g/kg) and high-dose IV steroids (methylprednisolone, 20 mg/kg/day). IV mannitol and hyperhydration were commenced to avoid free haemoglobinaemia-associated renal damage. The patient recovered after 1 week and was discharged, with a haemoglobin level of 71 g/L.

Six months later, the patient experienced a further episode of marked haemolysis that occurred after a red cell transfusion for vaso-occlusive crisis. He presented to hospital 5 days after the transfusion with a 48-hour history of increasing pain, increased jaundice and discoloured urine. His bilirubin level was 129 $\mu\text{mol/L}$ (reference range, $<10 \mu\text{mol/L}$) (unconjugated, 125 $\mu\text{mol/L}$; conjugated, 4 $\mu\text{mol/L}$), which was greater than a previous measurement of 77 $\mu\text{mol/L}$. Again, no red cell alloantibodies or autoantibodies were detected, and his reticulocyte count was elevated, at $303 \times 10^9/L$. His haemoglobin level continued to fall after admission, reaching 24 g/L after 24 hours. He was managed with further IVIg and high-dose steroids. In view of his ongoing marked, symptomatic anaemia after 3 days of this treatment, he was transfused with 250 mL of phenotypically matched red cells,

without complication, and was discharged 2 days later with a haemoglobin level of 71 g/L. He did not re-present with further haemolysis. Follow-up is ongoing, with management as clinically indicated.

This was a prolonged and dramatic event for the child and his family. Placing him on a regular transfusion program was discussed, but the risks of repeated transfusions and the possibility, although small, of another hyperhaemolysis event were considered to outweigh the benefits of maintaining a higher haemoglobin level in a child who was thriving. If a regular transfusion program were to be considered again in the future, it would be prudent to assess the risks and benefits of exchange transfusion. Treatment with erythropoietin was also considered but deemed unnecessary at this time. Pretransfusion steroid treatment was considered an appropriate addition to the future management of this patient.

Discussion

Sickle cell disease is increasing in incidence in Australia due to immigration patterns involving increasing numbers of people from regions where the disease is common, such as Africa.¹ Although hyperhaemolysis in sickle cell disease has been recognised for more than 20 years, this case highlights it as an uncommon but potentially life-threatening complication, involving destruction of both donor and recipient red cells after red cell transfusion.²⁻⁵ Haemolysis can be rapid and profound. Onset is usually within 7 days after transfusion and is characterised by severe intravascular haemolysis, haemoglobinuria, and anaemia to levels of haemoglobin lower than pretransfusion levels. Reticulocytopenia may be present. Hyperhaemolysis has also been reported in patients with β thalassaemia and myelofibrosis.^{6,7} Recurrent hyperhaemolysis is unusual in children, with few available data pertaining to this phenomenon in the paediatric population. The information provided by patients in whom recurrence occurs is particularly valuable. Human leukocyte antigen antibodies were not tested in the patient described here, nor were his haemoglobin S levels followed during these episodes. Measurement of these parameters in other affected patients would add to the body of data and knowledge on hyperhaemolysis.

The exact mechanisms responsible for hyperhaemolysis are not fully understood. High-performance liquid chromatography analysis of urine in a patient with haemoglobinuria after red cell transfusion demonstrates both donor and recipient haemoglobin.⁸ In typical haemolytic transfusion reactions, alloimmune mechanisms are responsible, with the development of red cell antibodies in the patient against antigens present on donor red cells. The antigens most commonly implicated are those of the Rhesus, Kell, Kidd, Duffy and MNSs blood group systems. Haemolytic reactions

NOTABLE CASES

due to alloimmunisation are associated with haemolysis of donor red cells only, and laboratory testing usually leads to identification of the causative red cell antibodies. Suggested mechanisms for hyperhaemolysis include cytokine-mediated haemolysis or uncontrolled macrophage activation.⁹⁻¹¹

Recommended treatment of hyperhaemolysis includes avoidance of transfusion where possible and immune modulation with steroids and IVIG.^{3,5,8} The mechanism of action of steroids and immunoglobulin has not been fully elucidated, but these treatments have been demonstrated to be effective in a number of patients. Repeated exposure to red cells after recovery may lead to recurrence of hyperhaemolysis, as seen in this case. Erythropoietin may be used in an attempt to reduce the need for further exposure to transfused red cells.³ Prompt referral for expert management is essential.

Hyperhaemolysis is an uncommon but potentially fatal complication of sickle cell disease. Recognition of this unusual complication is important for medical staff who manage patients with sickle cell disease in Australia.

Competing interests

None identified.

Author details

Ian C Stokes, BSc(Hons), BMBS, Paediatric Registrar, Department of Clinical Haematology¹

Peter A Downie, MB BS, FRACP, Director of Clinical Oncology¹

Erica M Wood, MB BS, FRACP, FRCPA, National Transfusion Medicine Services Manager²

Donald K Bowden, MB BS, FRACP, Haematologist and Head of Thalassaemia Services Victoria³

Paul T Monagle, MB BS, FRACP, FRCPA, Head of Haematology¹

Chris D Barnes, MB BS, FRACP, FRCPA, Haematologist¹

¹ Royal Children's Hospital, Melbourne, VIC.

² Australian Red Cross Blood Service, Melbourne, VIC.

³ Thalassaemia Service, Monash Medical Centre, Melbourne, VIC.

Correspondence: i.stokes74@gmail.com

References

- 1 Australian Bureau of Statistics. 2006 Census tables: Australia. Canberra: ABS, 2007.
- 2 Petz LD, Calhoun L, Shulman IA, et al. The sickle cell hemolytic transfusion reaction syndrome. *Transfusion* 1997; 37: 382-392.
- 3 Talano JA, Hillery CA, Gottschall JL, et al. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. *Pediatrics* 2003; 111 (6 Pt 1): e661-e665.
- 4 Ballas SK, Marcolina MJ. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. *Transfusion* 2006; 46: 105-110.
- 5 Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. *Transfusion* 2002; 42: 37-43.
- 6 Grainger JD, Makar Y, McManus A, Wynn R. Refractory hyperhaemolysis in a patient with beta-thalassaemia major. *Transfus Med* 2001; 11: 55-57.
- 7 Treleaven JG, Win N. Hyperhaemolysis syndrome in a patient with myelofibrosis. *Hematology* 2004; 9: 147-149.
- 8 Win N, Yeghen T, Needs M, et al. Use of intravenous immunoglobulin and intravenous methylprednisolone in hyperhaemolysis syndrome in sickle cell disease. *Hematology* 2004; 9: 433-436.
- 9 King KE, Shirey RS, Lankiewicz MW, et al. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. *Transfusion* 1997; 37: 376-381.
- 10 Garratty G. Severe reactions associated with transfusion of patients with sickle cell disease. *Transfusion* 1997; 37: 357-361.
- 11 Win N, Doughty H, Telfer P, et al. Hyperhemolytic transfusion reaction in sickle cell disease. *Transfusion* 2001; 41: 323-328.

(Received 20 Jul 2009, accepted 7 Dec 2009)

□

PBS information: This product is not listed on the PBS.

PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING.

Full Product Information is available from sanofi-aventis australia pty ltd. XATRAL® SR (alfuzosin hydrochloride).

INDICATIONS Treatment of the functional symptoms of benign prostatic hyperplasia. DOSAGE AND ADMINISTRATION One 10mg tablet daily to be taken immediately after the meal. Tablets should be swallowed whole. CONTRAINDICATIONS Must not be administered to patients with known hypersensitivity to alfuzosin hydrochloride, to patients with a history of orthostatic hypotension or hepatic insufficiency. Contraindicated in combination with other alpha-blockers. PRECAUTIONS Administer carefully to patients with: known hypersensitivity to α_1 -blockers; or symptomatic orthostatic hypotension; or who have had a pronounced hypotensive response to another α_1 -blocker. Postural hypotension with or without symptoms (dizziness, fatigue, sweating) may develop within a few hours following administration. These effects are usually transient, occur at the beginning of treatment and do not usually prevent the continuation of treatment. Patients should be warned about possible occurrence. Administer carefully to patients treated with antihypertensives. Blood pressure should be monitored regularly, especially at the beginning of treatment. Xatral SR should not be prescribed alone in coronary patients: specific treatment for coronary insufficiency should be continued. If angina reappears or worsens, Xatral SR should be discontinued. Safety in patients with Parkinson's disease, multiple sclerosis, unstable angina or severe heart failure has not been formally assessed. Carcinoma of the prostate should be excluded in any patients for whom alfuzosin therapy is being considered for presumed BPH. Adverse effects such as vertigo, dizziness and asthenia may occur and should be taken into account when driving vehicles and operating machinery. Patients should be warned that the tablet should be swallowed whole. Any other mode of administration, such as crushing, chewing, grinding or pounding to powder should be avoided. 'Intra-operative Floppy Iris Syndrome' (IFS) has been observed during cataract surgery in some patients on, or previously treated with, tamsulosin and other α_1 -blockers. The possibility of a class effect cannot be excluded. Pregnancy: Category B2. Alfuzosin in not intended for use in women. Lactation: Alfuzosin in not intended for use in women. There are no animal or human data indicating whether alfuzosin is excreted in breast milk. INTERACTIONS Contraindicated in use with other α_1 -blockers e.g. prazosin, terazosin, doxazosin, tamsulosin. Avoid the following combinations: Non-selective α_1 -blockers: phentolamine, labetalol and phenoxybenzamine. The following combinations are to be taken into account: Combination with general anaesthetics (alfuzosin treatment should be stopped 24 hours prior to surgery); Concomitant use with antihypertensives; Concomitant use with nitrates; Concomitant use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole and ritonavir (since alfuzosin blood levels are increased). Exercise caution with medications metabolised by or inhibiting CYP3A4 (such as modern α_1 -blockers), herbal remedies (particularly St. John's Wort, Milk thistle) and grapefruit juice. ADVERSE EFFECTS Adverse effects include the following: Common: asthenia, faintness/dizziness, headache, nausea, abdominal pain/gastralgia; Uncommon: chest pain, hypotension (including postural), syncope, palpitations, tachycardia, pruritus, rhinitis; Very rare: angina pectoris (in patients with pre-existing coronary artery disease); Frequency unknown: intraoperative floppy iris syndrome, priapism. Please refer to full PI for further adverse effects. sanofi-aventis australia pty ltd, ABN 31 008 558 807, 12-24 Talavera Rd, Macquarie Park NSW 2113. © Registered trademark. 1/10 SAX0023_MJA PUBLICIS LIFE BRANDS

sanofi aventis
Because health matters

Sanofi Aventis
XATRAL
p283